Beyond Fixed Dosing: The Drug Titration Paradox and the Case for Personalized Medicine Strategies

Summary: A hidden flaw in clinical trial analysis—ignoring titration history—leads to the paradoxical observation that higher doses correlate with weaker effects. This article dissects two competing drug development strategies: Strategy P (population outcomes for fixed or hybrid dosing) and Strategy I (individual outcomes for science-based titration algorithms). Using the propofol paradox from a 2021 CPT paper as a case study, we explore how non-random assignment biases results, why personalized dosing improves efficacy and safety across anaesthetics, warfarin, basal insulins, and alcohol, and what it takes for regulators, payers, physicians, and drug companies to align on titration algorithms. The piece argues that the current regulatory preference for fixed-dose simplicity inadvertently discourages optimal individualization, and proposes a new evidence-generation paradigm for the future of drug therapy development.

Introduction: The Drug Titration Paradox

In 2021, a paper published in Clinical Pharmacology and Therapeutics (CPT) reported a striking observation: “While analysing clinical data where an anaesthetic was titrated based on an objective measure of drug effect, we observed paradoxically that greater effect was associated with lesser dose” (Source: CPT 2021, “The Drug Titration Paradox: Correlation of More Drug With Less Effect in Clinical Data”). This statement encapsulates a fundamental analytical flaw that pervades much of clinical trial design.

The paradox arises when researchers use only the final maintenance dose of a drug in a response-guided titration regimen, ignoring the entire titration history. For propofol—a widely used anaesthetic—patients who required higher maintenance doses to achieve the same depth of anaesthesia were systematically different from those who could be maintained on lower doses. The resulting data set shows a negative correlation: “higher” final doses appear to be associated with weaker effects, even though the drug is being correctly titrated to a target effect. This is not a biological anomaly; it is a statistical artifact caused by non-random assignment.

The tension exposed by this paradox is central to modern drug development. Fixed-dose regimens are simple to study, easy for regulators to evaluate, and straightforward for physicians to prescribe. Yet they are often suboptimal for individual patients, who may require dose adjustments based on metabolic rate, disease severity, genetic polymorphisms, or concomitant medications. Personalized dosing—using a science-based titration algorithm—can improve both efficacy and safety, but it requires a far more complex evidence-generation framework and stakeholder alignment.

Strategy P vs. Strategy I: Two Competing Development Paths

Drug developers face a fundamental choice between two overarching strategies, here termed Strategy P (Population) and Strategy I (Individual).

Strategy P relies on population-average outcomes to obtain regulatory approval for fixed-dose or hybrid dosing with simple titration (e.g., “start at dose X, increase if tolerated”). This path is the industry default. It minimizes the complexity of clinical trials, facilitates large sample sizes, and produces results that are easily interpretable by regulators and payers. The fixed-dose approach works well when a drug has a wide therapeutic window and low inter-individual variability—sitagliptin, a DPP-4 inhibitor for type 2 diabetes, is frequently cited as a rare “diamond” drug where fixed dosing may be optimal (Source: CPT 2021 and other references).

Strategy I shifts the focus to individual-level outcomes. The goal is to design and validate a science-based dose titration algorithm that adapts to each patient’s response in real time. This strategy demands more data: pharmacokinetic/pharmacodynamic modeling, dynamic response metrics, and often biomarker-based guidance. The payoff can be substantial. Across several therapeutic areas, personalized dosing has demonstrated improvements in efficacy, safety, or both compared with fixed dosing. Notable examples include anaesthetic agents (where titration to an electroencephalogram-derived index reduces over- and underdosing), warfarin (where pharmacogenetic algorithms lower bleeding and thromboembolism rates), basal insulins (where patient-specific titration improves glycemic control while reducing hypoglycemia), and alcohol (where individualised dosing of disulfiram or naltrexone aligns with pharmacogenetic profiles). In each case, the population-level benefit of titration is masked if only final doses are analysed, but individual-level data reveal clear gains.

The Hidden Flaw: Non-Random Assignment and Analytical Pitfalls

The core analytical error identified in the CPT paper is the use of final maintenance dose as a predictor of effect in response-guided titration designs. When a clinician titrates a drug to a target effect (e.g., sedation score, INR, blood glucose), the dose an individual ultimately receives is a function of their sensitivity, not a randomly assigned treatment level. The patients who need higher doses are systematically different: they may have more severe disease, faster drug clearance, or receptor polymorphisms that reduce sensitivity. This is non-random assignment within the trial.

Consequently, a simple correlation analysis comparing final dose to achieved effect will show a paradoxical negative slope—more drug associated with less effect—because the high-dose group includes the least responsive patients. The propofol example is illustrative: lower maintenance doses were associated with greater depth of anaesthesia (as measured by a processed EEG index), exactly because the anaesthesiologist had already adjusted the infusion rate to keep each patient at the same target level. The dose itself becomes an inverse proxy for sensitivity.

This flaw has broad implications. Many approved drugs with recommended titration schemes (e.g., beta-blockers, antidepressants, anticoagulants) have been studied using only final dose data for subgroup analyses. The resulting evidence may systematically underestimate the value of dose individualization. Re-analysing such trials with appropriate methods—such as repeated measures models that incorporate the titration trajectory, or instrumental variable approaches—could alter risk-benefit assessments.

The Case for Personalized Dosing: Evidence Across Therapeutic Areas

The benefits of personalized dosing extend beyond the propofol case. For warfarin, a drug with a narrow therapeutic index and high inter-patient variability, pharmacogenetic-guided dosing algorithms have been shown to reduce major bleeding events while maintaining time in therapeutic range comparable to or better than fixed dosing (Source: multiple randomized trials, e.g., EU-PACT and COAG). Basal insulins, such as insulin glargine and detemir, are approved with forced-titration algorithms that mandate upward or downward adjustments based on fasting glucose. Studies that compare algorithm-based dosing to “usual care” (often an ad hoc fixed dose) consistently demonstrate better glycemic control with no increase in severe hypoglycemia. For alcohol use disorder, naltrexone response is linked to specific opioid receptor genotypes; individualized dosing schemes that account for these differences improve abstinence rates.

In all these examples, the key enabler is a validated titration algorithm that uses a measurable surrogate endpoint. The algorithm must be prospectively studied, not just described in labeling. Strategy I requires that a drug’s approval be based on the algorithm’s performance, not solely on a fixed-dose comparison. This shifts the evidence requirement from “Is drug X effective at dose Y?” to “Does algorithm Z yield better outcomes than a control (e.g., usual care or a fixed dose)?”

Sitagliptin remains an outlier. Its pharmacokinetics are relatively predictable across populations, with minimal metabolism and a wide safety margin. For such drugs, the cost and complexity of developing a titration algorithm are not justified. But for the majority of drugs with narrow therapeutic windows or high variability, Strategy I offers a path to improved patient outcomes.

Aligning Stakeholders: The Challenge of Implementing Titration Algorithms

Despite the clinical logic, widespread adoption of titration algorithms faces substantial hurdles. Each stakeholder group has distinct incentives.

Regulators (e.g., FDA, EMA) traditionally evaluate fixed-dose studies because they provide clear evidence of efficacy and safety. A trial comparing an algorithm to usual care introduces additional variables—clinician compliance, site-to-site variation in monitoring—that complicate labeling. Regulators require that the algorithm be precisely defined, that its effect be separable from the drug’s intrinsic properties, and that it be validated in the intended population. This raises the evidence bar.
Payers (insurers, health technology assessment bodies) are concerned with net health benefit and cost-effectiveness. A titration algorithm may improve outcomes but also increase monitoring costs or require training. If the algorithm is not mandatory in labeling, payers may see it as optional and decline to reimburse it separately. Conversely, if it reduces adverse events and hospitalizations, it could be cost-saving.
Physicians must be trained and willing to follow an algorithm, which may conflict with clinical autonomy. Without strong evidence that the algorithm outperforms their own judgment, adoption will be slow.
Drug companies face the highest barrier. Developing a titration algorithm requires additional trials, often with complex designs (e.g., adaptive dose-finding, multi-step algorithms). This increases development time and cost. For a drug that could be approved with a simple fixed-dose study, companies have a strong financial disincentive to pursue Strategy I unless the differentiation leads to a competitive advantage (e.g., safer profile, broader labeling, premium pricing).

Alignment will require a shift in how evidence is generated and evaluated. One possible path is the use of hybrid designs: a fixed-dose pivotal study that provides the core efficacy proof, supplemented by a smaller but rigorous algorithmic trial that demonstrates safety and effectiveness of the titration method. Regulators could then approve the drug with a labeling recommendation for the algorithm, conditional on post-marketing study.

Future Predictions: Toward a New Evidence-Generation Paradigm

The drug titration paradox has exposed a systematic weakness in current clinical trial analysis. As data science and digital tools (e.g., continuous glucose monitors, wearable EEG, smartphone-based symptom tracking) become more common, the ability to capture titration trajectories in real time will improve. This will make it harder for manufacturers and regulators to ignore the non-random assignment bias.

In the next five to ten years, several trends are likely:

Increased use of dynamic modeling: Pharmacometric models that incorporate dose-response over time will become standard in regulatory submissions for drugs with titration protocols. The FDA’s recent draft guidance on adaptive designs and model-informed drug development points in this direction.
Labeling for algorithms, not just doses: Some drugs launched tomorrow may carry labeling that specifies a titration algorithm rather than discrete fixed-dose regimens. This has already occurred for advanced insulin analogues and may expand to anticoagulants, psychiatric drugs, and immunomodulators.
Regulatory incentives for Strategy I: Health authorities could offer expedited review, extended market exclusivity, or reduced post-marketing commitments for drugs that demonstrate superior outcomes through a validated titration algorithm. This would offset the higher development costs for companies.
Payer differentiation: Payers may create formulary tiers that favor drugs with algorithm-based dosing when they reduce complications. The cost-effectiveness models will need to incorporate the algorithm’s impact on real-world adherence and outcomes.
Physician decision support integration: Titration algorithms will increasingly be embedded in electronic health records and clinical decision support systems, reducing the cognitive load on clinicians and enabling standardized application.

The drug titration paradox is not merely a statistical curiosity. It is a call to action. For decades, the drug development ecosystem has prioritized simplicity over individualization. The evidence is now clear that response-guided titration data cannot be analysed by final dose alone (Source: CPT 2021). The path forward—Strategy I—promises better outcomes across dozens of therapeutic areas, but only if stakeholders can collaborate to design, validate, and implement science-based titration algorithms. The market is already moving; the coming years will determine how fast the shift occurs.